| __timestamp | BeiGene, Ltd. | HUTCHMED (China) Limited |
|---|---|---|
| Wednesday, January 1, 2014 | 21862000 | 72049000 |
| Thursday, January 1, 2015 | 58250000 | 110777000 |
| Friday, January 1, 2016 | 98033000 | 156328000 |
| Sunday, January 1, 2017 | 273992000 | 175820000 |
| Monday, January 1, 2018 | 707710000 | 143944000 |
| Tuesday, January 1, 2019 | 998528000 | 160152000 |
| Wednesday, January 1, 2020 | 1365534000 | 188519000 |
| Friday, January 1, 2021 | 1624145000 | 258234000 |
| Saturday, January 1, 2022 | 1926983000 | 311103000 |
| Sunday, January 1, 2023 | 379920000 | 384447000 |
Unleashing the power of data
In the rapidly evolving biopharmaceutical landscape, cost efficiency is paramount. BeiGene, Ltd. and HUTCHMED (China) Limited, two prominent players, have shown contrasting trends in their cost of revenue from 2014 to 2023. BeiGene's cost of revenue surged by over 8,700% from 2014 to 2022, peaking in 2022 before a notable drop in 2023. This reflects their aggressive expansion and investment in R&D. Conversely, HUTCHMED maintained a more stable trajectory, with a 434% increase over the same period, indicating a more conservative growth strategy. The data highlights BeiGene's rapid scaling efforts, while HUTCHMED's steadier approach suggests a focus on sustainable growth. As these companies navigate the competitive market, their cost management strategies will be crucial in determining their long-term success.
Analyzing Cost of Revenue: Johnson & Johnson and BeiGene, Ltd.
Cost of Revenue Comparison: Merck & Co., Inc. vs BeiGene, Ltd.
Comparing Cost of Revenue Efficiency: Vertex Pharmaceuticals Incorporated vs BeiGene, Ltd.
Cost Insights: Breaking Down BeiGene, Ltd. and Halozyme Therapeutics, Inc.'s Expenses
Cost of Revenue Comparison: BeiGene, Ltd. vs Lantheus Holdings, Inc.
Cost of Revenue Comparison: Incyte Corporation vs HUTCHMED (China) Limited
Cost of Revenue Comparison: Intra-Cellular Therapies, Inc. vs HUTCHMED (China) Limited
Analyzing Cost of Revenue: BioMarin Pharmaceutical Inc. and HUTCHMED (China) Limited
Cost of Revenue Comparison: Cytokinetics, Incorporated vs HUTCHMED (China) Limited
Analyzing Cost of Revenue: Amneal Pharmaceuticals, Inc. and HUTCHMED (China) Limited
Cost of Revenue: Key Insights for CRISPR Therapeutics AG and HUTCHMED (China) Limited
Bausch Health Companies Inc. vs HUTCHMED (China) Limited: Efficiency in Cost of Revenue Explored